Home Healthcare Biotechnology Vaccine Adjuvants Market

Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type (Mineral Salt-based Adjuvant, Adjuvant Emulsions, Liposome Adjuvants, Tensoactive Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), Carbohydrate Adjuvants, Others), By Usage Type (Active Immunostimulants, Carriers, Vehicle Adjuvants), By Disease Type (Infectious diseases, Cancer), By Application (Research Applications, Commercial Applications) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Vaccine Adjuvants Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Mineral Salt-based Adjuvant
    2. Adjuvant Emulsions
    3. Liposome Adjuvants
    4. Tensoactive Adjuvants
    5. Bacteria-derived Adjuvants
    6. Virus-like Particles (VLP)
    7. Carbohydrate Adjuvants
    8. Others
  2. Vaccine Adjuvants Market, By Usage Type 2022-2034 (USD MILLION/ Units)
    1. Active Immunostimulants
    2. Carriers
    3. Vehicle Adjuvants
  3. Vaccine Adjuvants Market, By Disease Type 2022-2034 (USD MILLION/ Units)
    1. Infectious diseases
    2. Cancer
  4. Vaccine Adjuvants Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Research Applications
    2. Commercial Applications
  5. Regional Vaccine Adjuvants Market
    1. North America
      1. North America Vaccine Adjuvants Market By Type 2022-2034 (USD MILLION/ Units)
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
      2. North America Vaccine Adjuvants Market By Usage Type 2022-2034 (USD MILLION/ Units)
        1. Active Immunostimulants
        2. Carriers
        3. Vehicle Adjuvants
      3. North America Vaccine Adjuvants Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Infectious diseases
        2. Cancer
      4. North America Vaccine Adjuvants Market By Application 2022-2034 (USD MILLION/ Units)
        1. Research Applications
        2. Commercial Applications
      5. U.S.
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      6. Canada
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
    2. Europe
      1. Europe Vaccine Adjuvants Market By Type 2022-2034 (USD MILLION/ Units)
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
      2. Europe Vaccine Adjuvants Market By Usage Type 2022-2034 (USD MILLION/ Units)
        1. Active Immunostimulants
        2. Carriers
        3. Vehicle Adjuvants
      3. Europe Vaccine Adjuvants Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Infectious diseases
        2. Cancer
      4. Europe Vaccine Adjuvants Market By Application 2022-2034 (USD MILLION/ Units)
        1. Research Applications
        2. Commercial Applications
      5. U.K.
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      6. Germany
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      7. France
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      8. Spain
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      9. Italy
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      10. Russia
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      11. Nordic
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      12. Benelux
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      13. Rest of Europe
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
    3. APAC
      1. APAC Vaccine Adjuvants Market By Type 2022-2034 (USD MILLION/ Units)
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
      2. APAC Vaccine Adjuvants Market By Usage Type 2022-2034 (USD MILLION/ Units)
        1. Active Immunostimulants
        2. Carriers
        3. Vehicle Adjuvants
      3. APAC Vaccine Adjuvants Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Infectious diseases
        2. Cancer
      4. APAC Vaccine Adjuvants Market By Application 2022-2034 (USD MILLION/ Units)
        1. Research Applications
        2. Commercial Applications
      5. China
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      6. Korea
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      7. Japan
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      8. India
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      9. Australia
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      10. Taiwan
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      11. South East Asia
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      12. Rest of Asia-Pacific
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
    4. Middle East and Africa
      1. Middle East and Africa Vaccine Adjuvants Market By Type 2022-2034 (USD MILLION/ Units)
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
      2. Middle East and Africa Vaccine Adjuvants Market By Usage Type 2022-2034 (USD MILLION/ Units)
        1. Active Immunostimulants
        2. Carriers
        3. Vehicle Adjuvants
      3. Middle East and Africa Vaccine Adjuvants Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Infectious diseases
        2. Cancer
      4. Middle East and Africa Vaccine Adjuvants Market By Application 2022-2034 (USD MILLION/ Units)
        1. Research Applications
        2. Commercial Applications
      5. UAE
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      6. Turkey
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      7. Saudi Arabia
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      8. South Africa
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      9. Egypt
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      10. Nigeria
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      11. Rest of MEA
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
    5. LATAM
      1. LATAM Vaccine Adjuvants Market By Type 2022-2034 (USD MILLION/ Units)
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
      2. LATAM Vaccine Adjuvants Market By Usage Type 2022-2034 (USD MILLION/ Units)
        1. Active Immunostimulants
        2. Carriers
        3. Vehicle Adjuvants
      3. LATAM Vaccine Adjuvants Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Infectious diseases
        2. Cancer
      4. LATAM Vaccine Adjuvants Market By Application 2022-2034 (USD MILLION/ Units)
        1. Research Applications
        2. Commercial Applications
      5. Brazil
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      6. Mexico
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      7. Argentina
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      8. Chile
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      9. Colombia
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
      10. Rest of LATAM
        1. Mineral Salt-based Adjuvant
        2. Adjuvant Emulsions
        3. Liposome Adjuvants
        4. Tensoactive Adjuvants
        5. Bacteria-derived Adjuvants
        6. Virus-like Particles (VLP)
        7. Carbohydrate Adjuvants
        8. Others
        9. Active Immunostimulants
        10. Carriers
        11. Vehicle Adjuvants
        12. Infectious diseases
        13. Cancer
        14. Research Applications
        15. Commercial Applications
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.